Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Marks first international filing for Evofem’s single-dose oral treatment
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Subscribe To Our Newsletter & Stay Updated